Back to Insights
    Healthcare AI 7 min read

    Ambient AI is moving fast in healthcare. How do suppliers differentiate when everyone sounds the same?

    By Clarity Media Co.Published

    Ambient voice technology has moved quickly from novelty to national conversation. NHS England published guidance on the use of AI-enabled ambient scribing products in health and care settings in April 2025, now in its third version following an update in July 2026.

    On 29 July 2026 the MHRA published guidance clarifying the regulatory status of ambient voice technologies used in the NHS, distinguishing products limited to transcription, summarising, drafting and suggestion for clinician review from those supporting diagnosis, treatment or automated clinical action, which are regulated as medical devices. NHS England communicated the position to system leaders the same day.

    For suppliers, the effect is a category that is simultaneously legitimised, crowded and closely watched.

    Everyone is saying the same four things

    Saves clinician time, reduces administrative burden, improves the consultation, integrates with your systems. These are the claims of the category, not of any individual product. When every supplier leads with them, none of them differentiate.

    The uncomfortable implication is that most ambient AI marketing is currently doing category education on behalf of the market rather than building preference for a specific product.

    Differentiate on precision, not on adjectives

    Where is your product actually used, and in which conversations. What does the output look like, and who checks it. How does it behave in the parts of the workflow that are messy. What does implementation involve, realistically, for a team with no spare capacity.

    Answering those questions publicly and specifically separates you from suppliers who only answer them under questioning.

    Be clear about scope

    Given the published distinction between products that support clinician-reviewed documentation and those that support clinical decisions, being explicit and accurate about where your product sits is now part of clear commercial communication as well as a matter for your regulatory colleagues.

    Ambiguity here is commercially expensive. It slows conversations that could have been simple.

    Credibility beyond the product page

    In a crowded category buyers look for signals outside the sales material: how the organisation talks about deployment realities, what its leaders say publicly, whether its perspective on the category is worth reading. That is where differentiation is currently cheapest to build, because so few suppliers are doing it well.

    This article refers to a position current at the date above and is reviewed when the underlying guidance or policy changes. Clarity Media Co. comments on the marketing and commercial implications of developments in Digital Health and HealthTech. We do not provide clinical, regulatory, DTAC or legal advice.

    Ready to make your technology easy to understand?

    Tell us where you are and where you want to be. We will come back with clear, honest guidance on the marketing that will move you forward.

    No obligation and no hard sell. You leave the call with an honest view of your marketing, whether or not we work together.